BridgeBio Oncology Therapeutics, Inc. Balance Sheet
BBOT / Health Care|2 years of annual SEC 10-K data (FY2023-FY2024)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 2 fiscal years. All figures from audited SEC 10-K filings.
BridgeBio Oncology Therapeutics, Inc. had $194M in total assets with negative shareholders' equity of $4M as of FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| Current Assets | $1.9M | - |
| Total Assets | $194.4M | $332.9K |
| Current Liabilities | $187.5K | $396.5K |
| Shareholders' Equity | -$3.7M | -$63.6K |